NIS study determining prevalence of HER2-low in metastatic breast cancer patients

Trial Identifier: D9673R00037
Sponsor: AstraZeneca
Start Date: April 2024
Primary Completion Date: October 2025
Study Completion Date: October 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Argentina Rosario, Argentina
Brazil Sao Paulo, Brazil
Dominican Republic Santo Domingo, Dominican Republic
India, Delhi Delhi, India, 110085
India, Delhi Delhi, India, 110005
India, Delhi Delhi, India, 110029
India, Karnataka Bengaluru, Karnataka, India, 560017
India, Kerala Kochi, Kerala, India, 682041
India, Maharashtra Mumbai, Maharashtra, India, 400012
India, Odisha Bhubaneshwar, Odisha, India, 751003
India, Punjab Mohali, Punjab, India, 160055
India, Telangana Hyderabad, Telangana, India, 500034
India, Uttar Pradesh Varanasi, Uttar Pradesh, India, 221005
Indonesia Jakarta, Indonesia
Malaysia Kaula Lumpur, Malaysia
Malaysia Subang Jaya, Malaysia
Mexico Ciudad de Mexico, Mexico
Panama Panama, Panama
Philippines Quezon city, Philippines
Singapore Singapore, Singapore
Thailand Bangkok, Thailand
Vietnam Hanoi, Vietnam
Vietnam Ho Chi Minh, Vietnam
Vietnam Hue, Vietnam